TNBC

TNBC

Dr. Rebecca Shatsky discusses clinical trials on adjuvant carboplatin and PARP inhibitors in triple-negative breast cancer (TNBC) at OncUpdates.

TNBC

03/05/2026

Adjuvant Carboplatin and PARP Inhibitor Combination Trials in TNBC

Rebecca Shatsky, MDRahul Gosain, MD, MBARohit Gosain, MD

1. Expert doctors Mariam Haji Ahmad and Alexis Levee discuss early use of first-line ADCs in breast cancer treatment and advancements in sequencing technology for improved patient outcomes.

TNBC

01/17/2026

Impact of ADCs in Early TNBC Treatment

Mariam Haji Ahmad, MBBChAlexis Levee, MD

Antibody-drug conjugates reshaping triple-negative breast cancer treatment algorithm, oncologists discuss advances.

TNBC

01/15/2026

ADCs in TNBC: Current Data and Unanswered Questions

Pietro De Placido, MDDionisia Quiroga, DO, PhD

1. Expert discussion on TROP2 ADC options in PD-L1-negative TNBC featuring Alexis LeVee and Paolo Tarantino, MD.

TNBC

01/01/2026

Anti-TROP-2 ADCs in PD-L1-Negative TNBC

Alexis Levee, MDPaolo Tarantino, MD

Accelerating breast cancer treatment research by integrating Sacituzumab govitecan, Pembrolizumab, with expert clinicians Dionisia Quiroga, DO, PhD, and Erika Hamilton, MD, in Las Vegas skyline background.

TNBC

12/25/2025

SABCS 2025: Clarifying Where Sacituzumab Govitecan Fits in the Breast Cancer Treatment Landscape

Erika Hamilton, MD, FASCODionisia Quiroga, DO, PhD

Advances in early-stage and metastatic triple-negative breast cancer (TNBC) treatments, featuring expert insights from Dr. Briana To, highlighting evolving oncologic approaches and clinical research.

TNBC

12/19/2025

Evolving Approaches to Early-Stage and Metastatic TNBC

Briana To, DO, PhD